David Prosser: Big pharma bites tongue on healthcare
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Outlook Why the eerie silence from Britain's biggest pharmaceutical companies? On Monday, after more than a year of horsetrading, the US House of Representatives finally approved President Barack Obama's healthcare reforms. Yet 48 hours later, Britain's three FTSE 100 pharma giants – GlaxoSmithKline, AstraZeneca and Shire – have still not told us what they think.
This is a major shake-up of the biggest healthcare market in the world. All three companies have a significant exposure to it. But while The Independent has pressed GSK, AstraZeneca and Shire to give their verdict, none has been prepared to put their head above the parapet.
Cynical observers may conclude that their silence reflects satisfaction with the reforms tempered with caution about being seen to crow about something of such enormous political controversy.
Although the pharmaceutical industry will face some upfront costs from the reforms, it has avoided some of the more troublesome outcomes. Above all, there will be no price caps introduced on their products – and state-by-state negotiations on price will continue.
Compensating for the upfront hit, meanwhile, is the knowledge that these reforms will deliver in excess of 30 million potential new customers – drug sales should rise by 6 to 8 per cent within the next 10 years as a consequence of the legislation.
This has been a job of political lobbying well done. The American pharmaceutical association which represents the industry has spent heavily promoting the case for healthcare reform. No doubt our publicity-shy pharma bosses have been much more vocal in privately voicing their thanks.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments